RxDoctor Payments Data

Manisha Kamat, MD

Psychiatry · Chester, PANPI 1679755128

Payments from drug & device makers

$5,118in general payments, 2019–2025

Across 208 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$548
  • Teva Pharmaceuticals USA, Inc.$540
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$523
  • Neurocrine Biosciences, Inc.$461
  • Takeda Pharmaceuticals U.S.A., Inc.$244
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,79194%
  • Education$3276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,118 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$158,901
Medicare patients
134
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Venlafaxine Hcl ErVenlafaxine Hcl35$3,960
Duloxetine Hcl83$2,684
Bupropion XlBupropion Hcl65$2,339
Lurasidone Hcl14$1,906
Escitalopram Oxalate87$1,477
Quetiapine Fumarate ErQuetiapine Fumarate18$1,253
Quetiapine Fumarate65$1,100
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$1,068
Divalproex Sodium ErDivalproex Sodium31$890
Mirtazapine69$766
Buspirone Hcl29$728
Trazodone Hcl70$684
Sertraline Hcl38$641
Lamotrigine64$518
Bupropion Hcl SrBupropion Hcl18$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$52$64138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →